Targeted Protein Degradation and Regulation with Molecular Glue:
Past and Recent Discoveries

doi:10.2174/0929867328666210806113949
摘要

靶向治疗的研究和临床环境的发展受到癌症化疗进展的启发，即使用小分子和单克隆抗体靶向非感染性慢性疾病的特定疾病相关基因和蛋白质。除了作为药物发现方式的常规蛋白质抑制和激活策略外，使用分子胶进行靶向蛋白质降解和调节的新方法已成为药物发现的一种有吸引力的方法。从机制上讲，分子胶通过形成三元复合物作为蛋白质-蛋白质相互作用 (PPI) 调节剂来触发原本不相互作用的蛋白质之间的相互作用。在过去的几十年里，人们对新的分子胶及其作用机制进行了积极的研究。一种免疫调节性酰亚胺药物沙利度胺及其衍生物已用于临床
关键词: 分子胶，蛋白质降解，蛋白质-蛋白质相互作用，沙利度胺，CR8，E7820。
« Previous Next »
[1] 
Toure, M.; Crews, C.M. Small-molecule protacs: new approaches to protein degradation. Angew. Chem. Int. Ed. Engl.,  2016, 55(6), 1966-1973.
[http://dx.doi.org/10.1002/anie.201507978] [PMID:  26756721] 
[2] 
Stanton, B.Z.; Chory, E.J.; Crabtree, G.R. Chemically induced proximity in biology and medicine. Science,  2018, 359(6380)eaao5902
[http://dx.doi.org/10.1126/science.aao5902] [PMID:  29590011] 
[3] 
Hughes, S.J.; Ciulli, A. Molecular recognition of ternary complexes: a new dimension in the structure-guided design of chemical degraders. Essays Biochem.,  2017, 61(5), 505-516.
[http://dx.doi.org/10.1042/EBC20170041] [PMID:  29118097] 
[4] 
Chopra, R.; Sadok, A.; Collins, I. A critical evaluation of the approaches to targeted protein degradation for drug discovery. Drug Discov. Today. Technol.,  2019, 31, 5-13.
[http://dx.doi.org/10.1016/j.ddtec.2019.02.002] [PMID:  31200859] 
[5] 
Du, X.; Volkov, O.A.; Czerwinski, R.M.; Tan, H.; Huerta, C.; Morton, E.R.; Rizzi, J.P.; Wehn, P.M.; Xu, R.; Nijhawan, D.; Wallace, E.M. Structural basis and kinetic pathway of RBM39 recruitment to DCAF15 by a sulfonamide molecular glue E7820.Structure, 2019, 27(11), 1625-1633
	e1623., 
[http://dx.doi.org/10.1016/j.str.2019.10.005] 
[6] 
Słabicki, M.; Kozicka, Z.; Petzold, G.; Li, Y-D.; Manojkumar, M.; Bunker, R.D.; Donovan, K.A.; Sievers, Q.L.; Koeppel, J.; Suchyta, D.; Sperling, A.S.; Fink, E.C.; Gasser, J.A.; Wang, L.R.; Corsello, S.M.; Sellar, R.S.; Jan, M.; Gillingham, D.; Scholl, C.; Fröhling, S.; Golub, T.R.; Fischer, E.S.; Thomä, N.H.; Ebert, B.L. The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K. Nature,  2020, 585(7824), 293-297.
[http://dx.doi.org/10.1038/s41586-020-2374-x] [PMID:  32494016] 
[7] 
Banik, S.M.; Pedram, K.; Wisnovsky, S.; Ahn, G.; Riley, N.M.; Bertozzi, C.R. Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature,  2020, 584(7820), 291-297.
[http://dx.doi.org/10.1038/s41586-020-2545-9] [PMID:  32728216] 
[8] 
Bosch, J. PPI inhibitor and stabilizer development in human diseases. Drug Discov. Today. Technol.,  2017, 24, 3-9.
[http://dx.doi.org/10.1016/j.ddtec.2017.10.004] [PMID:  29233297] 
[9] 
Okuro, K.; Kinbara, K.; Tsumoto, K.; Ishii, N.; Aida, T. Molecular glues carrying multiple guanidinium ion pendants via an oligoether spacer: stabilization of microtubules against depolymerization. J. Am. Chem. Soc.,  2009, 131(5), 1626-1627.
[http://dx.doi.org/10.1021/ja800491v] [PMID:  19146374] 
[10] 
Schmidtchen, F.P.; Berger, M. Artificial organic host molecules for anions. Chem. Rev.,  1997, 97(5), 1609-1646.
[http://dx.doi.org/10.1021/cr9603845] [PMID:  11851460] 
[11] 
Lagoutte, R.; Winssinger, N. Following the lead from nature with covalent inhibitors. Chimia (Aarau),  2017, 71(10), 703-711.
[http://dx.doi.org/10.2533/chimia.2017.703] [PMID:  29070414] 
[12] 
Isobe, Y.; Okumura, M.; McGregor, L.M.; Brittain, S.M.; Jones, M.D.; Liang, X.; White, R.; Forrester, W.; McKenna, J.M.; Tallarico, J.A.; Schirle, M.; Maimone, T.J.; Nomura, D.K. Manumycin polyketides act as molecular glues between UBR7 and P53. Nat. Chem. Biol.,  2020, 16(11), 1189-1198.
[http://dx.doi.org/10.1038/s41589-020-0557-2] [PMID:  32572277] 
[13] 
Sheskin, J. Thalidomide in the treatment of lepra reactions. Clin. Pharmacol. Ther.,  1965, 6, 303-306.
[http://dx.doi.org/10.1002/cpt196563303] [PMID:  14296027] 
[14] 
Singhal, S.; Mehta, J.; Desikan, R.; Ayers, D.; Roberson, P.; Eddlemon, P.; Munshi, N.; Anaissie, E.; Wilson, C.; Dhodapkar, M.; Zeddis, J.; Barlogie, B. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med.,  1999, 341(21), 1565-1571.
[http://dx.doi.org/10.1056/NEJM199911183412102] [PMID:  10564685] 
[15] 
Bramuzzo, M.; Ventura, A.; Martelossi, S.; Lazzerini, M. Thalidomide for inflammatory bowel disease: Systematic review. Medicine (Baltimore),  2016, 95(30)e4239
[http://dx.doi.org/10.1097/MD.0000000000004239] [PMID:  27472695] 
[16] 
Srinivasan, R.; Akobeng, A.K. Thalidomide and thalidomide analogues for induction of remission in Crohn’s disease. Cochrane Database Syst. Rev., 2009, (2)CD007350
[http://dx.doi.org/10.1002/14651858.CD007350.pub2] [PMID:  19370684] 
[17] 
Akobeng, A.K.; Stokkers, P.C. Thalidomide and thalidomide analogues for maintenance of remission in Crohn’s disease. Cochrane Database Syst. Rev., 2009, (2)CD007351
[http://dx.doi.org/10.1002/14651858.CD007351.pub2] [PMID:  19370685] 
[18] 
Fisher, S.L.; Phillips, A.J. Targeted protein degradation and the enzymology of degraders. Curr. Opin. Chem. Biol.,  2018, 44, 47-55.
[http://dx.doi.org/10.1016/j.cbpa.2018.05.004] [PMID:  29885948] 
[19] 
Gerry, C.J.; Schreiber, S.L. Unifying principles of bifunctional, proximity-inducing small molecules. Nat. Chem. Biol.,  2020, 16(4), 369-378.
[http://dx.doi.org/10.1038/s41589-020-0469-1] [PMID:  32198490] 
[20] 
Schreiber, S.L. The rise of molecular glues. Cell,  2021, 184(1), 3-9.
[http://dx.doi.org/10.1016/j.cell.2020.12.020] [PMID:  33417864] 
[21] 
Simonetta, K.R.; Taygerly, J.; Boyle, K.; Basham, S.E.; Padovani, C.; Lou, Y.; Cummins, T.J.; Yung, S.L.; von Soly, S.K.; Kayser, F.; Kuriyan, J.; Rape, M.; Cardozo, M.; Gallop, M.A.; Bence, N.F.; Barsanti, P.A.; Saha, A. Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction. Nat. Commun.,  2019, 10(1), 1402.
[http://dx.doi.org/10.1038/s41467-019-09358-9] [PMID:  30926793] 
[22] 
Knobloch, J.; Rüther, U. Shedding light on an old mystery: thalidomide suppresses survival pathways to induce limb defects. Cell Cycle,  2008, 7(9), 1121-1127.
[http://dx.doi.org/10.4161/cc.7.9.5793] [PMID:  18418038] 
[23] 
Ito, T.; Ando, H.; Suzuki, T.; Ogura, T.; Hotta, K.; Imamura, Y.; Yamaguchi, Y.; Handa, H. Identification of a primary target of thalidomide teratogenicity. Science,  2010, 327(5971), 1345-1350.
[http://dx.doi.org/10.1126/science.1177319] [PMID:  20223979] 
[24] 
Eichner, R.; Heider, M.; Fernández-Sáiz, V.; van Bebber, F.; Garz, A.K.; Lemeer, S.; Rudelius, M.; Targosz, B.S.; Jacobs, L.; Knorn, A.M.; Slawska, J.; Platzbecker, U.; Germing, U.; Langer, C.; Knop, S.; Einsele, H.; Peschel, C.; Haass, C.; Keller, U.; Schmid, B.; Götze, K.S.; Kuster, B.; Bassermann, F. Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity. Nat. Med.,  2016, 22(7), 735-743.
[http://dx.doi.org/10.1038/nm.4128] [PMID:  27294876] 
[25] 
Ito, T.; Handa, H. Molecular mechanisms of thalidomide and its derivatives. Proc. Jpn. Acad., Ser. B, Phys. Biol. Sci.,  2020, 96(6), 189-203.
[http://dx.doi.org/10.2183/pjab.96.016] [PMID:  32522938] 
[26] 
Mori, T.; Ito, T.; Liu, S.; Ando, H.; Sakamoto, S.; Yamaguchi, Y.; Tokunaga, E.; Shibata, N.; Handa, H.; Hakoshima, T. Structural basis of thalidomide enantiomer binding to cereblon. Sci. Rep.,  2018, 8(1), 1294.
[http://dx.doi.org/10.1038/s41598-018-19202-7] [PMID:  29358579] 
[27] 
Fischer, E.S.; Böhm, K.; Lydeard, J.R.; Yang, H.; Stadler, M.B.; Cavadini, S.; Nagel, J.; Serluca, F.; Acker, V.; Lingaraju, G.M.; Tichkule, R.B.; Schebesta, M.; Forrester, W.C.; Schirle, M.; Hassiepen, U.; Ottl, J.; Hild, M.; Beckwith, R.E.; Harper, J.W.; Jenkins, J.L.; Thomä, N.H. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature,  2014, 512(7512), 49-53.
[http://dx.doi.org/10.1038/nature13527] [PMID:  25043012] 
[28] 
Kim, H.K.; Ko, T.H.; Nyamaa, B.; Lee, S.R.; Kim, N.; Ko, K.S.; Rhee, B.D.; Park, C.S.; Nilius, B.; Han, J. Cereblon in health and disease. Pflugers Arch.,  2016, 468(8), 1299-1309.
[http://dx.doi.org/10.1007/s00424-016-1854-1] [PMID:  27343012] 
[29] 
Ito, T.; Handa, H. Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs. Int. J. Hematol.,  2016, 104(3), 293-299.
[http://dx.doi.org/10.1007/s12185-016-2073-4] [PMID:  27460676] 
[30] 
Vargesson, N. Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res. C Embryo Today,  2015, 105(2), 140-156.
[http://dx.doi.org/10.1002/bdrc.21096] [PMID:  26043938] 
[31] 
Fischer, E.S.; Park, E.; Eck, M.J.; Thomä, N.H. SPLINTS: small-molecule protein ligand interface stabilizers. Curr. Opin. Struct. Biol.,  2016, 37, 115-122.
[http://dx.doi.org/10.1016/j.sbi.2016.01.004] [PMID:  26829757] 
[32] 
Li, Y.; Yang, J.; Aguilar, A.; McEachern, D.; Przybranowski, S.; Liu, L.; Yang, C.Y.; Wang, M.; Han, X.; Wang, S. Discovery of MD-224 as a first-in-class, highly potent, and efficacious proteolysis targeting chimera murine double minute 2 degrader capable of achieving complete and durable tumor regression. J. Med. Chem.,  2019, 62(2), 448-466.
[http://dx.doi.org/10.1021/acs.jmedchem.8b00909] [PMID:  30525597] 
[33] 
Yi, K.; Xu, J.; Peng, B. The association between GSTP1 polymorphism and pre-eclampsia risk: a system review and meta-analysis. Arch. Gynecol. Obstet.,  2020, 301(1), 11-18.
[http://dx.doi.org/10.1007/s00404-019-05411-6] [PMID:  31875251] 
[34] 
Tao, N.N.; Zhou, H.Z.; Tang, H.; Cai, X.F.; Zhang, W.L.; Ren, J.H.; Zhou, L.; Chen, X.; Chen, K.; Li, W.Y.; Liu, B.; Yang, Q.X.; Cheng, S.T.; Huang, L.X.; Huang, A.L.; Chen, J. Sirtuin 3 enhanced drug sensitivity of human hepatoma cells through glutathione S-transferase pi 1/JNK signaling pathway. Oncotarget,  2016, 7(31), 50117-50130.
[http://dx.doi.org/10.18632/oncotarget.10319] [PMID:  27367026] 
[35] 
Yang, M.; Li, Y.; Shen, X.; Ruan, Y.; Lu, Y.; Jin, X.; Song, P.; Guo, Y.; Zhang, X.; Qu, H.; Shao, Y.; Quan, C. CLDN6 promotes chemoresistance through GSTP1 in human breast cancer. J. Exp. Clin. Cancer Res.,  2017, 36(1), 157.
[http://dx.doi.org/10.1186/s13046-017-0627-9] [PMID:  29116019] 
[36] 
Yang, J.; Li, Y.; Aguilar, A.; Liu, Z.; Yang, C.Y.; Wang, S. Simple structural modifications converting a bona fide MDM2 PROTAC degrader into a molecular glue molecule: a cautionary tale in the design of PROTAC degraders. J. Med. Chem.,  2019, 62(21), 9471-9487.
[http://dx.doi.org/10.1021/acs.jmedchem.9b00846] [PMID:  31560543] 
[37] 
Bettayeb, K.; Oumata, N.; Echalier, A.; Ferandin, Y.; Endicott, J.A.; Galons, H.; Meijer, L. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene,  2008, 27(44), 5797-5807.
[http://dx.doi.org/10.1038/onc.2008.191] [PMID:  18574471] 
[38] 
Petzold, G.; Fischer, E.S.; Thomä, N.H. Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase. Nature,  2016, 532(7597), 127-130.
[http://dx.doi.org/10.1038/nature16979] [PMID:  26909574] 
[39] 
Lui, G.Y.L.; Grandori, C.; Kemp, C.J. CDK12: an emerging therapeutic target for cancer. J. Clin. Pathol.,  2018, 71(11), 957-962.
[http://dx.doi.org/10.1136/jclinpath-2018-205356] [PMID:  30104286] 
[40] 
Delehouzé, C.; Godl, K.; Loaëc, N.; Bruyère, C.; Desban, N.; Oumata, N.; Galons, H.; Roumeliotis, T.I.; Giannopoulou, E.G.; Grenet, J.; Twitchell, D.; Lahti, J.; Mouchet, N.; Galibert, M.D.; Garbis, S.D.; Meijer, L. CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells. Oncogene,  2014, 33(50), 5675-5687.
[http://dx.doi.org/10.1038/onc.2013.513] [PMID:  24317512] 
[41] 
Semba, T.; Funahashi, Y.; Ono, N.; Yamamoto, Y.; Sugi, N.H.; Asada, M.; Yoshimatsu, K.; Wakabayashi, T. An angiogenesis inhibitor E7820 shows broad-spectrum tumor growth inhibition in a xenograft model: possible value of integrin alpha2 on platelets as a biological marker. Clin. Cancer Res.,  2004, 10(4), 1430-1438.
[http://dx.doi.org/10.1158/1078-0432.CCR-0109-03] [PMID:  14977846] 
[42] 
Han, T.; Goralski, M.; Gaskill, N.; Capota, E.; Kim, J.; Ting, T.C.; Xie, Y.; Williams, N.S.; Nijhawan, D. Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15. Science,  2017, 356(6336)eaal3755
[http://dx.doi.org/10.1126/science.aal3755] [PMID:  28302793] 
[43] 
Uehara, T.; Minoshima, Y.; Sagane, K.; Sugi, N.H.; Mitsuhashi, K.O.; Yamamoto, N.; Kamiyama, H.; Takahashi, K.; Kotake, Y.; Uesugi, M.; Yokoi, A.; Inoue, A.; Yoshida, T.; Mabuchi, M.; Tanaka, A.; Owa, T. Selective degradation of splicing factor CAPERα by anticancer sulfonamides. Nat. Chem. Biol.,  2017, 13(6), 675-680.
[http://dx.doi.org/10.1038/nchembio.2363] [PMID:  28437394] 
[44] 
McGaughey, G.B.; Gagné, M.; Rappé, A.K. pi-Stacking interactions. Alive and well in proteins. J. Biol. Chem.,  1998, 273(25), 15458-15463.
[http://dx.doi.org/10.1074/jbc.273.25.15458] [PMID:  9624131] 
[45] 
Baek, K.; Schulman, B.A. Molecular glue concept solidifies. Nat. Chem. Biol.,  2020, 16(1), 2-3.
[http://dx.doi.org/10.1038/s41589-019-0414-3] [PMID:  31819271] 
[46] 
Bury, M.; Andolfi, A.; Rogister, B.; Cimmino, A.; Mégalizzi, V.; Mathieu, V.; Feron, O.; Evidente, A.; Kiss, R. Fusicoccin a, a phytotoxic carbotricyclic diterpene glucoside of fungal origin, reduces proliferation and invasion of glioblastoma cells by targeting multiple tyrosine kinases. Transl. Oncol.,  2013, 6(2), 112-123.
[http://dx.doi.org/10.1593/tlo.12409] [PMID:  23544164] 
[47] 
Stevers, L.M.; Sijbesma, E.; Botta, M.; MacKintosh, C.; Obsil, T.; Landrieu, I.; Cau, Y.; Wilson, A.J.; Karawajczyk, A.; Eickhoff, J.; Davis, J.; Hann, M.; O’Mahony, G.; Doveston, R.G.; Brunsveld, L.; Ottmann, C. Modulators of 14-3-3 protein-protein interactions. J. Med. Chem.,  2018, 61(9), 3755-3778.
[http://dx.doi.org/10.1021/acs.jmedchem.7b00574] [PMID:  28968506] 
[48] 
Layfield, R.; Fergusson, J.; Aitken, A.; Lowe, J.; Landon, M.; Mayer, R.J. Neurofibrillary tangles of Alzheimer’s disease brains contain 14-3-3 proteins. Neurosci. Lett.,  1996, 209(1), 57-60.
[http://dx.doi.org/10.1016/0304-3940(96)12598-2] [PMID:  8734909] 
[49] 
Ayuke, G.H. Baker, R. Beausejour, J. C. Bedano, K. Birkhofer, E. Blanchart, B. Blossey, T. Bolger, R. L. Bradley, M. A. Callaham, Y. Capowiez, M. E. Caulfield, A. Choi, F. V. Crotty, A. Davalos, D. J. Diaz Cosin, A. Dominguez, A. E. Duhour, N. van Eekeren, C. Emmerling, L. B. Falco, R. Fernandez, S. J. Fonte, C. Fragoso, A. L. C. Franco, M. Fugere, A. T. Fusilero, S. Gholami, M. J. Gundale, M. Gutierrez Lopez, D. K. Hackenberger, L. M. Hernandez, T. Hishi, A. R. Holdsworth, M. Holmstrup, K. N. Hopfensperger, E. Huerta Lwanga, V. Huhta, T. T. Hurisso, B. V. Iannone III, M. Iordache, M. Joschko, N. Kaneko, R. Kanianska, A. M. Keith, C. A. Kelly, M. L. Kernecker, J. Klaminder, A. W. Kone, Y. Kooch, S. T. Kukkonen, H. Lalthanzara, D. R. Lammel, I. M. Lebedev, Y. Li, J. B. Jesus Lidon, N. K. Lincoln, S. R. Loss, R. Marichal, R. Matula, J. H. Moos, G. Moreno, A. Moron-Rios, B. Muys, J. Neirynck, L. Norgrove, M. Novo, V. Nuutinen, V. Nuzzo, M. Rahman P, J. Pansu, S. Paudel, G. Peres, L. Perez-Camacho, R. Pineiro, J.-F. Ponge, M. I. Rashid, S. Rebollo, J. Rodeiro-Iglesias, M. A. Rodriguez, A. M. Roth, G. X. Rousseau, A. Rozen, E. Sayad, L. van Schaik, B. C. Scharenbroch, M. Schirrmann, O. Schmidt, B. Schroder, J. Seeber, M. P. Shashkov, J. Singh, S. M. Smith, M. Steinwandter, J. A. Talavera, D. Trigo, J. Tsukamoto, A. W. de Valenca, S. J. Vanek, I. Virto, A. A. Wackett, M. W. Warren, N. H. Wehr, J. K. Whalen, M. B. Wironen, V. Wolters, I. V. Zenkova, W. Zhang, E. K. Cameron, N Eisenhauer. Erratum for the report “Global distribution of earthworm diversity. Science,  2020, 369(6503)
[50] 
Würtele, M.; Jelich-Ottmann, C.; Wittinghofer, A.; Oecking, C. Structural view of a fungal toxin acting on a 14-3-3 regulatory complex. EMBO J.,  2003, 22(5), 987-994.
[http://dx.doi.org/10.1093/emboj/cdg104] [PMID:  12606564] 
[51] 
Inoue, T.; Higuchi, Y.; Yoneyama, T.; Lin, B.; Nunomura, K.; Honma, Y.; Kato, N. Semisynthesis and biological evaluation of a cotylenin A mimic derived from fusicoccin A. Bioorg. Med. Chem. Lett.,  2018, 28(4), 646-650.
[http://dx.doi.org/10.1016/j.bmcl.2018.01.030] [PMID:  29398541] 
[52] 
Harmange Magnani, C.S.; Maimone, T.J. Fusicoccin keeps getting stickier: modulation of an adaptor protein interactome with a molecular glue leads to neurite outgrowth. Cell Chem. Biol.,  2020, 27(6), 635-637.
[http://dx.doi.org/10.1016/j.chembiol.2020.05.011] [PMID:  32559498] 
[53] 
Bartel, B.; Wünning, I.; Varshavsky, A. The recognition component of the N-end rule pathway. EMBO J.,  1990, 9(10), 3179-3189.
[http://dx.doi.org/10.1002/j.1460-2075.1990.tb07516.x] [PMID:  2209542] 
[54] 
Bachmair, A.; Finley, D.; Varshavsky, A. In vivo half-life of a protein is a function of its amino-terminal residue. Science,  1986, 234(4773), 179-186.
[http://dx.doi.org/10.1126/science.3018930] [PMID:  3018930] 
[55] 
Tasaki, T.; Mulder, L.C.; Iwamatsu, A.; Lee, M.J.; Davydov, I.V.; Varshavsky, A.; Muesing, M.; Kwon, Y.T. A family of mammalian E3 ubiquitin ligases that contain the UBR box motif and recognize N-degrons. Mol. Cell. Biol.,  2005, 25(16), 7120-7136.
[http://dx.doi.org/10.1128/MCB.25.16.7120-7136.2005] [PMID:  16055722] 
[56] 
Muday, G.K.; DeLong, A. Polar auxin transport: controlling where and how much. Trends Plant Sci.,  2001, 6(11), 535-542.
[http://dx.doi.org/10.1016/S1360-1385(01)02101-X] [PMID:  11701382] 
[57] 
Gray, W.M.; Kepinski, S.; Rouse, D.; Leyser, O.; Estelle, M. Auxin regulates SCF(TIR1)-dependent degradation of AUX/IAA proteins. Nature,  2001, 414(6861), 271-276.
[http://dx.doi.org/10.1038/35104500] [PMID:  11713520] 
[58] 
Skowyra, D.; Koepp, D.M.; Kamura, T.; Conrad, M.N.; Conaway, R.C.; Conaway, J.W.; Elledge, S.J.; Harper, J.W. Reconstitution of G1 cyclin ubiquitination with complexes containing SCFGrr1 and Rbx1. Science,  1999, 284(5414), 662-665.
[http://dx.doi.org/10.1126/science.284.5414.662] [PMID:  10213692] 
[59] 
Cardozo, T.; Pagano, M. The SCF ubiquitin ligase: insights into a molecular machine. Nat. Rev. Mol. Cell Biol.,  2004, 5(9), 739-751.
[http://dx.doi.org/10.1038/nrm1471] [PMID:  15340381] 
[60] 
Calderon-Villalobos, L.I.; Tan, X.; Zheng, N.; Estelle, M. Auxin perception-structural insights. Cold Spring Harb. Perspect. Biol.,  2010, 2(7)a005546
[http://dx.doi.org/10.1101/cshperspect.a005546] [PMID:  20504967] 
[61] 
Mogaki, R.; Okuro, K.; Ueki, R.; Sando, S.; Aida, T. Molecular glue that spatiotemporally turns on protein-protein interactions. J. Am. Chem. Soc.,  2019, 141(20), 8035-8040.
[http://dx.doi.org/10.1021/jacs.9b02427] [PMID:  30977371] 
[62] 
Goodson, H.V.; Jonasson, E.M. Microtubules and microtubule-associated proteins. Cold Spring Harb. Perspect. Biol.,  2018, 10(6)a022608
[http://dx.doi.org/10.1101/cshperspect.a022608] [PMID:  29858272] 
[63] 
Garzoni, M.; Okuro, K.; Ishii, N.; Aida, T.; Pavan, G.M. Structure and shape effects of molecular glue on supramolecular tubulin assemblies. ACS Nano,  2014, 8(1), 904-914.
[http://dx.doi.org/10.1021/nn405653k] [PMID:  24351029] 
[64] 
Huang, Q.; Li, F.; Liu, X.; Li, W.; Shi, W.; Liu, F.F.; O’Sullivan, B.; He, Z.; Peng, Y.; Tan, A.C.; Zhou, L.; Shen, J.; Han, G.; Wang, X.J.; Thorburn, J.; Thorburn, A.; Jimeno, A.; Raben, D.; Bedford, J.S.; Li, C.Y. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat. Med.,  2011, 17(7), 860-866.
[http://dx.doi.org/10.1038/nm.2385] [PMID:  21725296] 
[65] 
Hentzen, N.B.; Mogaki, R.; Otake, S.; Okuro, K.; Aida, T. Intracellular photoactivation of caspase-3 by molecular glues for spatiotemporal apoptosis induction. J. Am. Chem. Soc.,  2020, 142(18), 8080-8084.
[http://dx.doi.org/10.1021/jacs.0c01823] [PMID:  32275408] 
[66] 
Zhou, Y.; Ye, H.; Chen, Y.; Zhu, R.; Yin, L. Photoresponsive drug/gene delivery systems. Biomacromolecules,  2018, 19(6), 1840-1857.
[http://dx.doi.org/10.1021/acs.biomac.8b00422] [PMID:  29701952] 
[67] 
Yang, G.; Wu, L.; Chen, G.; Jiang, M. Precise protein assembly of array structures. Chem. Commun. (Camb.),  2016, 52(70), 10595-10605.
[http://dx.doi.org/10.1039/C6CC04190F] [PMID:  27384233] 
[68] 
Luo, Q.; Hou, C.; Bai, Y.; Wang, R.; Liu, J. Protein assembly: versatile approaches to construct highly ordered nanostructures. Chem. Rev.,  2016, 116(22), 13571-13632.
[http://dx.doi.org/10.1021/acs.chemrev.6b00228] [PMID:  27587089] 
[69] 
Gordo, S.; Martos, V.; Santos, E.; Menéndez, M.; Bo, C.; Giralt, E.; de Mendoza, J. Stability and structural recovery of the tetramerization domain of p53-R337H mutant induced by a designed templating ligand. Proc. Natl. Acad. Sci. USA,  2008, 105(43), 16426-16431.
[http://dx.doi.org/10.1073/pnas.0805658105] [PMID:  18940924] 
[70] 
McGovern, R.E.; Fernandes, H.; Khan, A.R.; Power, N.P.; Crowley, P.B. Protein camouflage in cytochrome c-calixarene complexes. Nat. Chem.,  2012, 4(7), 527-533.
[http://dx.doi.org/10.1038/nchem.1342] [PMID:  22717436] 
[71] 
Renner, C.; Piehler, J.; Schrader, T. Arginine- and lysine-specific polymers for protein recognition and immobilization. J. Am. Chem. Soc.,  2006, 128(2), 620-628.
[http://dx.doi.org/10.1021/ja0560229] [PMID:  16402850] 
[72] 
Ingerman, L.A.; Cuellar, M.E.; Waters, M.L. A small molecule receptor that selectively recognizes trimethyl lysine in a histone peptide with native protein-like affinity. Chem. Commun. (Camb.),  2010, 46(11), 1839-1841.
[http://dx.doi.org/10.1039/C000255K] [PMID:  20198226] 
[73] 
McGovern, R.E.; McCarthy, A.A.; Crowley, P.B. Protein assembly mediated by sulfonatocalix[4]arene. Chem. Commun. (Camb.),  2014, 50(72), 10412-10415.
[http://dx.doi.org/10.1039/C4CC04897K] [PMID:  25068633] 
[74] 
McGovern, R.E.; Feifel, S.C.; Lisdat, F.; Crowley, P.B. Microscale crystals of cytochrome c and calixarene on electrodes: interprotein electron transfer between defined sites. Angew. Chem. Int. Ed. Engl.,  2015, 54(21), 6356-6359.
[http://dx.doi.org/10.1002/anie.201500191] [PMID:  25833222] 
[75] 
Matozaki, T.; Murata, Y.; Saito, Y.; Okazawa, H.; Ohnishi, H. Protein tyrosine phosphatase SHP-2: a proto-oncogene product that promotes Ras activation. Cancer Sci.,  2009, 100(10), 1786-1793.
[http://dx.doi.org/10.1111/j.1349-7006.2009.01257.x] [PMID:  19622105] 
[76] 
Chan, R.J.; Feng, G.S. PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood,  2007, 109(3), 862-867.
[http://dx.doi.org/10.1182/blood-2006-07-028829] [PMID:  17053061] 
[77] 
Chen, Y.N.; LaMarche, M.J.; Chan, H.M.; Fekkes, P.; Garcia-Fortanet, J.; Acker, M.G.; Antonakos, B.; Chen, C.H.; Chen, Z.; Cooke, V.G.; Dobson, J.R.; Deng, Z.; Fei, F.; Firestone, B.; Fodor, M.; Fridrich, C.; Gao, H.; Grunenfelder, D.; Hao, H.X.; Jacob, J.; Ho, S.; Hsiao, K.; Kang, Z.B.; Karki, R.; Kato, M.; Larrow, J.; La Bonte, L.R.; Lenoir, F.; Liu, G.; Liu, S.; Majumdar, D.; Meyer, M.J.; Palermo, M.; Perez, L.; Pu, M.; Price, E.; Quinn, C.; Shakya, S.; Shultz, M.D.; Slisz, J.; Venkatesan, K.; Wang, P.; Warmuth, M.; Williams, S.; Yang, G.; Yuan, J.; Zhang, J.H.; Zhu, P.; Ramsey, T.; Keen, N.J.; Sellers, W.R.; Stams, T.; Fortin, P.D. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Nature,  2016, 535(7610), 148-152.
[http://dx.doi.org/10.1038/nature18621] [PMID:  27362227] 
[78] 
Neel, B.G.; Chan, G.; Dhanji, S. Handbook of cell signaling,
	Second; Bradshaw, R.A.; Dennis, E.A., Eds.; Academic
	Press: San Diego, , 2010; 2, pp. 771-809.
[79] 
LaRochelle, J.R.; Fodor, M.; Vemulapalli, V.; Mohseni, M.; Wang, P.; Stams, T.; LaMarche, M.J.; Chopra, R.; Acker, M.G.; Blacklow, S.C. Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition. Nat. Commun.,  2018, 9(1), 4508.
[http://dx.doi.org/10.1038/s41467-018-06823-9] [PMID:  30375388] 
[80] 
Pettersson, M.; Crews, C.M. PROteolysis targeting chimeras (PROTACs) - past, present and future. Drug Discov. Today. Technol.,  2019, 31, 15-27.
[http://dx.doi.org/10.1016/j.ddtec.2019.01.002] [PMID:  31200855] 
[81] 
Paiva, S.L.; Crews, C.M. Targeted protein degradation: elements of PROTAC design. Curr. Opin. Chem. Biol.,  2019, 50, 111-119.
[http://dx.doi.org/10.1016/j.cbpa.2019.02.022] [PMID:  31004963] 
[82] 
Burslem, G.M.; Crews, C.M. Proteolysis-targeting chimeras as therapeutics and tools for biological discovery. Cell,  2020, 181(1), 102-114.
[http://dx.doi.org/10.1016/j.cell.2019.11.031] [PMID:  31955850] 
[83] 
Edmondson, S.D.; Yang, B.; Fallan, C. Proteolysis targeting chimeras (PROTACs) in ‘beyond rule-of-five’ chemical space: Recent progress and future challenges. Bioorg. Med. Chem. Lett.,  2019, 29(13), 1555-1564.
[http://dx.doi.org/10.1016/j.bmcl.2019.04.030] [PMID:  31047748] 
[84] 
Lamming, D.W. Inhibition of the mechanistic target of Rapamycin (mTOR)-Rapamycin and beyond. Cold Spring Harb. Perspect. Med.,  2016, 6(5)a025924
[http://dx.doi.org/10.1101/cshperspect.a025924] [PMID:  27048303] 
Rights & Permissions Print Cite
Article Metrics
82
1
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/0929867328666210806113949	Print ISSN 0929-8673
Publisher Name Bentham Science Publisher	Online ISSN 1875-533X
当代药物化学

用分子胶水靶向蛋白质降解和调控：过去和最近的发现

摘要

当代药物化学

用分子胶水靶向蛋白质降解和调控：过去和最近的发现

摘要 Play Pause

Related Journals

Related Books

Related Articles

摘要
